Stay updated on MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page.

Latest updates to the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe Study Details page shows only minor formatting adjustments with no changes to core study content, including eligibility criteria, outcomes, or listed locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check31 days agoChange DetectedAdded a government-operating-status notice and a new version tag (v3.2.0) while removing the old version tag (v3.1.0).SummaryDifference1%

- Check38 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes provided.SummaryDifference0.0%

- Check52 days agoChange DetectedUpdated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed. No core content changes are evident.SummaryDifference0.1%

- Check59 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

- Check67 days agoChange DetectedThe web page has updated its facility name and location details, including specific addresses in South Korea and Japan, while also removing some previous location terms and drug information. Notably, the drug information for Durvalumab has been revised to include Tremelimumab.SummaryDifference2%

Stay in the know with updates to MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page.